SCHEMBL7781173

SCHEMBL7781173

O=C(NCCN1CC2CC(c3ccc4ccccc4c3)C2C1)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 1/20 0.47
DRD4 P21917 1/20 0.47
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
HTR1A P08908 7/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
THRB P10828 1/20 0.43
KMT2A Q03164 1/20 0.43
MCL1 Q07820 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
PTPN1 P18031 1/20 0.42
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7778696 0.89 PLD1 (0.50) PLD1CYP1A2CYP2D6CYP2C19NPC1
SCHEMBL7778688 0.88 PLD1 (0.50) PLD1CYP1A2CYP2D6CYP2C19HTR1A
SCHEMBL8877700 0.83 MAPT (0.43) PLD1SMN1; SMN2MAPTMEN1POLB
SCHEMBL7817609 0.81 HTR1A (0.46) PLD1DRD4CYP1A2CYP2D6CYP2C19
SCHEMBL7781216 0.79 HPGD (0.52) PLD1DRD4CYP1A2CYP2D6CYP2C19
SCHEMBL7778722 0.77 KDM1A (0.50) PLD1GAA
SCHEMBL7778614 0.75 POLB (0.65) SMN1; SMN2MAPTPOLB
SCHEMBL7781108 0.75 PLD1 (0.53) PLD1HTR1A
SCHEMBL8875335 0.75 LMNA (0.53) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL7774077 0.74 PLD1 (0.53) PLD1NPC1RAB9ASMN1; SMN2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1133293-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2001-09-19 EP disclosed
EP-0775113-B1 N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS BASF AG (DE) 2001-04-11 EP disclosed
WO-2000030639-A1 USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM BASF AKTIENGESELLSCHAFT (DE) 2000-06-02 WO disclosed
EP-0775113-A1 N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS BASF AKTIENGESELLSCHAFT (DE) 1997-05-28 EP disclosed
WO-1996004245-A1 N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS BASF AKTIENGESELLSCHAFT (DE) 1996-02-15 WO disclosed